Open AccessPlasma lipocalin‐2 levels in the preclinical stage of Alzheimer's disease
Author(s) -
Eruysal Emily,
Ravdin Lisa,
Kamel Hooman,
Iadecola Costantino,
Ishii Makoto
Publication year - 2019
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1016/j.dadm.2019.07.004
Subject(s) - lipocalin , cerebrospinal fluid , biomarker , pathogenesis , medicine , disease , pathology , alzheimer's disease , dementia , immunology , biology , biochemistry
Abstract Introduction Lipocalin‐2 is an acute‐phase protein with pleotropic functions that has been implicated in several diseases including Alzheimer's disease (AD). However, it is unknown if circulating lipocalin‐2 levels are altered in the preclinical stage of AD, where AD pathology has accumulated but cognition remains relatively intact. Methods In this cross‐sectional study, we used an immunoassay to measure plasma lipocalin‐2 levels in cognitively normal (Clinical Dementia Rating 0) elderly individuals. 38 of 156 subjects were classified as preclinical AD by cerebrospinal fluid criteria. Results Plasma lipocalin‐2 levels were higher in preclinical AD compared with control subjects and associated with cerebrospinal fluid amyloid‐beta 42 levels but not cerebrospinal fluid tau or phosphorylated‐tau 181 levels. Exploratory analyses revealed that plasma lipocalin‐2 was associated with executive function but not episodic memory. Discussion Collectively, these results raise the possibility that circulating lipocalin‐2 is involved early in AD pathogenesis and may represent an early blood biomarker of amyloid‐beta pathology.